NFKB1 and diabetes mellitus: Consistent with previous literature, in our study, Myr was found to reduce the AGEs/diabetes-induced activation of NF-κB and pro-inflammatory cytokine levels both in vitro (Fig. 2A and B) and in vivo (Fig. 7A and B), which contributes to its protection against DCM.